Presentation is loading. Please wait.

Presentation is loading. Please wait.

Rapamycin decreases PD-L1 expression in lung tumors in vivo.

Published by얘원 반 Modified over 5 years ago

Similar presentations

Presentation on theme: "Rapamycin decreases PD-L1 expression in lung tumors in vivo."— Presentation transcript:

1 Rapamycin decreases PD-L1 expression in lung tumors in vivo.
Rapamycin decreases PD-L1 expression in lung tumors in vivo. Immunohistochemical staining for pS6 or PD-L1 in lung tumors treated with vehicle or rapamycin from A/J mice exposed to the tobacco-carcinogen NNK (A), C57BL/6 KRAS LA2 mice (B), or dox-exposed FVB mEGFR+/CC10+ littermates (C). Bar graphs quantify decreased staining of pS6 and PD-L1. Scale bar, 10 μm. *, P ≤ 0.05 by unpaired Student t test. Kristin J. Lastwika et al. Cancer Res 2016;76: ©2016 by American Association for Cancer Research

Download ppt "Rapamycin decreases PD-L1 expression in lung tumors in vivo."

Similar presentations

Immunohistochemical staining for RXR subtypes within benign and endometrioid endometrial carcinoma. Immunohistochemical staining for RXR subtypes within.

Immunohistochemical staining for RXR subtypes within benign and endometrioid endometrial carcinoma. Immunohistochemical staining for RXR subtypes within.
Supplementary Table 1 Akt2 is required for NNK-induced lung tumorigenesis but not for urethane-induced lung tumorigenesis while Akt3 may act as a tumor.

Supplementary Table 1 Akt2 is required for NNK-induced lung tumorigenesis but not for urethane-induced lung tumorigenesis while Akt3 may act as a tumor.
18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.
25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.
Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.

Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent manner. Combined PLX3397 and PTX treatment inhibits metastasis in a CD8-dependent.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. A.

Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. Effect of plumbagin (PL) on the growth of prostate tumors in Pten-KO mice. A.
NICD1 immunohistochemical staining in normal and tumor tissue.

NICD1 immunohistochemical staining in normal and tumor tissue.
Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.
Expression of mutant EGFR and downstream signaling components in tumors of mice at survival endpoint. Expression of mutant EGFR and downstream signaling.

Expression of mutant EGFR and downstream signaling components in tumors of mice at survival endpoint. Expression of mutant EGFR and downstream signaling.
Combined HDAC and mTOR inhibitors kill NF1-mutant malignancies in vitro and in vivo. Combined HDAC and mTOR inhibitors kill NF1-mutant malignancies in.

Combined HDAC and mTOR inhibitors kill NF1-mutant malignancies in vitro and in vivo. Combined HDAC and mTOR inhibitors kill NF1-mutant malignancies in.
Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.
NOX1-deficient mice do not respond to GKT771 and exhibit reduced B16-F10 tumor growth associated with decreased production of angiogenic factors and minor.

NOX1-deficient mice do not respond to GKT771 and exhibit reduced B16-F10 tumor growth associated with decreased production of angiogenic factors and minor.
BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR signaling in the NNK-treated mice. BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR.

BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR signaling in the NNK-treated mice. BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR.
Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:

Metformin and rapamycin decreased tumor weights in obese prediabetic mice. Metformin and rapamycin decreased tumor weights in obese prediabetic mice. A:
NOX1-deficient mice do not respond to GKT771 and exhibit reduced tumor growth, angiogenesis, and lymphangiogenesis. NOX1-deficient mice do not respond.

NOX1-deficient mice do not respond to GKT771 and exhibit reduced tumor growth, angiogenesis, and lymphangiogenesis. NOX1-deficient mice do not respond.
CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.
Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.

Similar presentations

Ads by Google